fda compounding semaglutide crackdown 2025 news Drugmakers battle pharmacies over compounded Ozempic and Zepbound : Shots The FDA is proposing the

Retatrutide is a 39-amino-acid peptide coupled to a fatty diacid moiety

Some women find that stepping back to a lower dose and titrating up more slowly resolves the issue without sacrificing weight loss efficacy

Severe diarrhea or constipation that does not improve with dietary adjustments

Plans are more likely to cover a GLP-1 for an FDA-approved use such as type 2 diabetes, and many employer plans still exclude weight-loss coverage entirely

Adults With Type 2 Diabetes Lost Almost 20 Percent of Their Weight on Retatrutide Lilly released findings from two separate phase 3 clinical trials on Thursday, the first being TRIUMPH-2, which included about 1,150 adults who were overweight or had obesity and type 2 diabetes